Answers are grounded in this paper and cite their sources.
Heterozygous or homozygous MTHFR variants, especially a compound mutation, are associated with increased risk of VTE. Hyperhomocysteinemia does not correlate with MTHFR polymorphisms or VTE risk. Hence, MTHFR genotyping provides more consistent assessment of VTE risk. This information can be incorporated into risk stratification for early intervention and prophylaxis of VTE.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2017) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: